Vogt Hannah, Shinkwin Patrick, Huber Max E, Staffen Nico, Hübner Harald, Gmeiner Peter, Schiedel Matthias, Weikert Dorothee
Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Straße 10, 91058 Erlangen, Germany.
FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Str. 10, 91058 Erlangen, Germany.
ACS Pharmacol Transl Sci. 2024 Apr 18;7(5):1533-1545. doi: 10.1021/acsptsci.4c00086. eCollection 2024 May 10.
The membrane protein family of G protein-coupled receptors (GPCRs) represents a major class of drug targets. Over the last years, the presence of additional intracellular binding sites besides the canonical orthosteric binding pocket has been demonstrated for an increasing number of GPCRs. Allosteric modulators harnessing these pockets may represent valuable alternatives when targeting the orthosteric pocket is not successful for drug development. Starting from SBI-553, a recently discovered intracellular allosteric modulator for neurotensin receptor subtype 1 (NTSR1), we developed the fluorescent molecular probe . Compound binds to NTSR1 with an affinity of 0.68 μM in the presence of the agonist NT(8-13). NanoBRET-based ligand binding assays with were established to derive the affinity and structure-activity relationships for allosteric NTSR1 modulators in a direct and nonisotopic manner, thereby facilitating the search for and optimization of novel allosteric NTSR1 ligands. As a consequence of cooperativity between the ligands binding to the allosteric and orthosteric pocket, compound can also be used to investigate orthosteric NTSR1 agonists and antagonists. Moreover, employing as a probe in a drug library screening, we identified novel chemotypes as binders for the intracellular allosteric SBI-553 binding pocket of NTSR1 with single-digit micromolar affinity. These hits may serve as interesting starting points for the development of novel intracellular allosteric ligands for NTSR1 as a highly interesting yet unexploited drug target in the fields of pain and addiction disorder therapy.
G蛋白偶联受体(GPCRs)膜蛋白家族是一类主要的药物靶点。在过去几年中,越来越多的GPCRs被证明除了经典的正构结合口袋外,还存在额外的细胞内结合位点。当针对正构口袋进行药物开发不成功时,利用这些口袋的变构调节剂可能是有价值的替代物。从最近发现的神经降压素受体1型(NTSR1)的细胞内变构调节剂SBI-553开始,我们开发了荧光分子探针。在激动剂NT(8-13)存在的情况下,化合物以0.68 μM的亲和力与NTSR1结合。建立了基于纳米生物发光共振能量转移(NanoBRET)的配体结合测定法,以直接和非同位素的方式推导变构NTSR1调节剂的亲和力和构效关系,从而促进新型变构NTSR1配体的寻找和优化。由于结合到变构口袋和正构口袋的配体之间存在协同作用,化合物也可用于研究正构NTSR1激动剂和拮抗剂。此外,在药物库筛选中使用作为探针,我们鉴定出具有个位数微摩尔亲和力的新型化学类型作为NTSR1细胞内变构SBI-553结合口袋的结合剂。这些命中物可能作为开发新型细胞内变构配体的有趣起点,NTSR1是疼痛和成瘾障碍治疗领域中一个非常有趣但尚未开发的药物靶点。